| Project/Area Number |
24658099
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Applied biochemistry
|
|---|
| Research Institution | Fukuoka University |
|---|
Principal Investigator |
MIAKE Fumio 福岡大学, 薬学部, 教授 (50248522)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
KASHIGE Nobuhiro 福岡大学, 薬学部, 教授 (80185751)
SATHO Tomomitsu 福岡大学, 薬学部, 助教 (90369025)
|
|---|
| Research Collaborator |
HIRAMATSU Yukihiro 福岡大学, 大学院・薬学研究科, 大学院生
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥3,510,000 (Direct Cost: ¥2,700,000、Indirect Cost: ¥810,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Keywords | 乳酸菌 / CTB-YVAD融合体 / 抗炎症作用 / 炎症性腸疾患 / CTB-YVAD複合体 |
|---|
| Research Abstract |
Recombinant lactic acid bacteria (LAB) are used as bacterial vectors to deliver functional peptides to the intestine, and cholera toxin B subunit (CTB) can translocate into intestinal epithelial cells through GM1 ganglioside. To deliver the YVAD peptide, which has potential as a therapeutic agent for inflammatory bowel disease (IBD), to the intestine, we constructed LAB secreting a recombinant fusion protein of CTB with YVAD (CTB-YVAD). The present study demonstrated that CTB-YVAD bind to GM1 ganglioside, translocate into human intestinal epithelial cell line, and show the anti-inflammatory effects. Taken together, we showed potencies of peptide delivery system to the intestine used LAB and CTB, and new therapeutic agent for IBD used LAB secreting CTB-YVAD.
|
